• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1488987 Tri- and tetrapeptides KABI AB 21 Nov 1975 [5 Dec 1974] 48019/75 Heading C3H A peptide of formula or a salt thereof, wherein R 1 is hydrogen, C 1 - C 12 alkanoyl, benzoyl, cyclohexylcarbonyl, substituted benzoyl, benzenesulphonyl or toluene sulphonyl; R 2 is nitrophenyl, naphthyl, nitronaphthyl, methoxynaphthayl, quinoyl or nitroquinoyl; A 1 is a direct bond or Gly, Ala, Val, Leu, Ile, Pro, Met, Phe or Tyr; A 2 is Glu, Gln, Asp, Asn. Peptides of the invention claimed are: The following intermediates are isolated: TETRAPEPTIDES: Cbo, Bz and H-Ile-Glu (OBzl)-Gly-Arg(NO 2 )-p-NA; and HBr.H-Ile-Glu- Gly-Arg(NO 2 )-pNA. TRIPEPTIDE: Boc - Gly(OBzl) - Gly - Arg (NO 2 )-pN A. The dipeptide isolated is Cbo-Gly-Arg(NO 2 )- pNA. The peptides are chromogenic substrates for serine proteases, and may be used for the determination of factor Xa in blood.
    公开号:SU957762A3
    申请号:SU752197544
    申请日:1975-12-04
    公开日:1982-09-07
    发明作者:Эрик Аурелл Лейф；Геран Клаесон Карл
    申请人:Актиеболагет Каби (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a method for producing peptides — new biologically active compounds that can be used in biochemistry and medicine. In peptide chemistry, the method of gradually building up a peptide chain by condensation of activated amino acids, for example, activated ester methods, is widely used. The purpose of the invention is the synthesis of new peptides containing a chromogenic group that have interesting properties. This goal is achieved by those that; according to the method of obtaining peptides of the general formula A / 2. - Gly - Apr - NHR2, where R is hydrogen, benzoyl; p-nitroanilide; asparaginyl, glycyl, isrleicil, leucyl, valyl, propyl, tyrosyl, phenylalanil; glutamic acid, glutamine, aspartic acid or their salts, the compound of General formula IIjN-Rj, in which R has the indicated values is subjected to interaction with the corresponding amino acid and then the desired peptide structure is gradually increased by combining the remaining amino acids, and the RJ group is used as a protective group for the C-terminal carboxyl group of the first agly but acid. Combinations of amino acids using the activated ester method are used to build up the required peptide structure. In this stepwise synthesis of peptide derivatives, methods and protective groups well known in peptide chemistry are used: carbobenzoxy (Kbo), para-methoxycarbobenzoxy. (BOC), trifluoroacetyl (TFA) or formyl is used as amino-protecting groups; ". The carboxyl group is activated by conversion to various derivatives that can either be isolated or obtained in situ, for example, p-nitrophenyl ester, trichlorophenyl, pentachlorophenyl, N-hydroxysuccinimide, azide and acid anhydride, which can be symmetrical. asymmetrical. N-car bodiimide can also be activated, for example, N, M-dicyclohexylcarbodiimide. The terminal carboxyl group in the amino peptide derivative or derivative of the amino acid can be protected by esterifamine to methyl, ethyl or isopropyl ether or by conversion to an aniline chromophore derivative, which also performs the function of the protective group during the growth of the peptide chain. Those free functional groups that do not take part in the reaction during the synthesis of peptides or their derivatives can be protected by the following pattern. Protonization (NO / j or para-toluenesulfonyl (TOC) is used to protect the remaining arginyl-guanidine groups. Benzyl and t-butyl groups are used as protection of the carboxyl group in the glutamic acid and aspartic acid. For the analysis of eluates and products, chromatography in a thin layer of silica gel p254 (®rk) is used. The following solvent systems are used; L at a volume ratio of n-butanol: acetic acid: water equal. 3: 1: 1; C at a volume ratio of cGeny, n-propanol: ethyl acetate: water, equal to 7: 1: 2; D at a p-heptane: n-butanol: acetic acid volume ratio of 3: 2: 1; P at a volume ratio of chloroform: methanol, equal to 9: 1. After chromatography in a thin layer, the plates are viewed under UV light (254 Im) and then chlorine / toluidine is then drawn. The following agent is applied. The following amino acid residues are used. Amino acids. Free amino acids or peptides are indicated by the letter H on the amino group and OH on the carboxyl group. The amino group is always indicated, the left carboxyl group on the right. All used amino acids have the L-configuration, if not specified additionally. Ala-alanine; . . Gly-glycine; Arg-Arginine; Ilei isoleucine; Asp-asparagine; Leu-leucine; Lspa-aspartin Meth methionine; acid; Glu-glutamine; Fe-phenylalanine; Glu-gl12taminova Pro-proline; acid;. Tyr-tyrosine; Bart-Valine, Other abbreviations: Ace-acetyl; MkbO-methoxypheny azocarbobenzoxy Ats5 O-aceticMeOH-methanol; anhydride; . LTSON-acetic Otb-tert.butyloxy; acid; Bok-tert.butylOET-Etiloxy oxycarbonyl; BZOL-benzoyl; Ome-methyloxy; Bzl-benzyl; OPPP-para-nitrofexy; B32 O-benzoic Oisop-isopropyl anhydride; oxy; CBO-carbobenz-pNA-para-nitroanone hydroxy; lead; Dcgdy-dicyclohex-TFA-trifluoroacetyl; silcarbodiimide; . EtdN-triethylamine; TOC-pair-toluensulfonyl. In the examples, unless otherwise specified, temperature. Example: HC1 Bzl-Ilei-Glu-Gdy-Arg-PIA. 1a.Kbo-Gli-Arg (N02) -nHA (Mol. Weight 530.4). A solution of 5.0 g (10.6. Mmol) of Kbo-Arg (N0).-PNA in 21 ml of AcOH and 22 ml of 4 N. The HBr in AcOH under anhydrous conditions is stirred for 1 hour at room temperature, then slowly poured into 200 ml of ether with vigorous stirring. The ether solution is separated by decantation, and the resulting granular residue is treated twice with 100 ml of ether. After vacuuming over KOH and tablets, a hydrobromic salt of the amino acid derivative is obtained almost quantitatively (4.95 g). The product is homogeneous according to thin layer chromatography (those) in system A. The product is dissolved in 50 ml of distilled dimethylformamide, the solution is cooled to -10 ° C and triethanolamine is added to neutral pH (2.1 ml). Triethanolamine hydrobromide precipitated is filtered off and the filtrate is cooled to. 3.9 g (11.8 mmol) of Kbo-Gly-APNP was added to the solution, and the mixture was slowly warmed to room temperature. 3 h, the solution is cooled again and 0.54 g (5, 3 mmol) of triethanolamine are introduced. After 2-3 hours, the same amount of triethanolamine is added again. The reaction mixture is left overnight at room temperature, then it is evaporated in vacuo at 40 ° C. The remaining yellow oil is mixed thoroughly with 100 ml of distilled water. The water is drained and the washing is repeated two more times. The remaining oil is dissolved in the mountains than the KOH. Upon cooling, the product precipitates in crystalline form. Yield 4.2 g, the product is homogeneous according to TLC in the system P, U 0.16, tct -36 ° (with 0.50 methanol). Ib: Nok-Glu (and -rbzl) -Gly-Arg (KO2) -NA (mol. Weight 715.8). 2.65 g (5.0 mmol) of product 1a are decarbobenzoxylated and condensed with 2.5 g (5.5 mmol) of Boc-Glu (-Obb APP in accordance with Example 1a. The product is purified on a Sephadex ZH chromatographic column in methanol. Yield 3.25 g (91%). The product is homogeneous according to those in the Pf system (R / 0.22), 5 -34 ° (c 1.0, methanol).
    1c: Kbo-Ilen-Glu (y -Obzl) -Gly-Apg (N02) -PPA (Mol. Weight 862.9).
    1.08 g (1.5 mmol) of product Ib is dissolved in up to 4 l of trifluoroacetate. The solution is stirred for 1 hour at room temperature, then slowly poured into 75 ml of ether. During a strong remixing. The ethereal solution is decanted and the obtained granular residue is treated twice with 50 ml ether. After drying in vacuum over and KOH tablets at 30c, trifluoroacetic acid was obtained; salt of tripeptide production mail and quantitatively (l, OOr) 2Q The product is homogeneous according to TLC; the L. system.
    The product is dissolved in 20 ml of dimethylformamide. The solution is cooled to -10 ° C and neutralized with triethanolamine 25 (0.23 4 l), 0.65 g (1.68 mmol) of Kbo-Ile-OPNF is added and the temperature of the solution is slowly raised to room temperature. After 3 hours, the solution is cooled again to -10 ° C and 0.12 ml is added. triethanolamine. After 2-3 hours, triethanolamine is added again and the solution is left overnight. Then, the excess Kbo-Ile-OPNP is destroyed by adding 100 mg (1.4 mmol) of n-butylamine to the solution. After 30 minutes, the solution is evaporated in vacuum at 40 ° C. The residual oil is washed with three portions of distilled water. Caslo is dissolved in MeOH and purified by chromatography on Sephadexo ZH-20 in methano-40 le. The output of 1.07 g (83%). The product is homogeneous according to TLC in the system P ,, R 0,35gS «1: e-24 (SO, ZMEON: dimethylformamide 95: 5).
    Id: Bzl-Iley-Glu (J-Obzl) -Gly- 45 -Apr (N02) -nHA.
    260 mg (0.30 mmol) of 1c dicarbobenzoxylate product according to Example 1a. The product shows two spots on those in the L system, (R 0.45 CQ and 0.65), and using infrared spectroscopy, the product was found to be a mixture of PVG; E-Ilay-Glu (; f-ON) -Gli-Arg (L02) -PIA and HBH-N-Eli-Glu. (y-Obbl) -Gly-Arg (N0.) -PNA. This mixture and 800 mg (0.35 mmol) of benzoic anhydride interact under the conditions described in Example 1a. The product is purified on Sephadexo ZH-20 in methanol. Two fractions are obtained: pi - 130 mg, "3 | f -15 (with 0.50 CH, CN) pO Ri 0.20 in P and f - 105 Mrtoilo -11 ° (with 0.5, СНзСМ) And 0, 06 in r.
    From infrared spectroscopy, it has been found that these two fractions are Bel-i-Glu (AND-Obzl) - 65
    -Gli-Arg (N0;) - PIA and Bel-i-Glu-Gly-Arg (N0 2) .- ..
    When interacting with hydrogen fluoride, both fractions give the same final product 1e.
    1e: IS1 Bzl-ILEP-Glu-Gly-Apr-nflA (mol. Weight 734).
    100 mg (0.12 mmol) "; -product Id and 0.5 ml of anisole are placed in a reaction flask of the Sakakibar apparatus. 5 ml of dry hydrogen fluoride are distilled into the flask and the reaction mixture is left for 75 minutes at wasp. Then, hydrogen fluoride was distilled off under reduced pressure, the oily residue was dissolved in 10 ml of acetic acid and purified by chromatography on Sephadexo g-15 in 33% acetic acid (in water). Then the 1515 containing pure unprotected tetrapeptide derivative is lyophilized. The compound obtained is dissolved in a mixture of metaNOL: distilled water (95: 5) and chromatographed on a weakly basic Q AE-SephDex A-25 exchanger in chloride form, the same solvent mixture is used for elution. Methanol is removed from the eluate under reduced pressure and the remaining the aqueous solution is lyophilized. Yield 75 mg (85%), the product is homogeneous according to TLC in system A (Rf 0.48 o -40 ° (with 0.5, acetic acid in distilled water).
    Analysis for amino acids: 0.98 Eli 0.5 Glu, 0.98 Apr, 1.00 Gly.
    PRI me R II: 2NS1 N-Ipei-Glu-Gli-Arg-PIA.
    On: 2NS1 N-Ilay-Glu-Gli-Arg-PN (mol. Weight 666.6).
    100 mg (0.116 mmol) of the product 1c are treated with hydrogen fluoride and purified under the conditions described in Example 1a.
    - Yield 56 mg (73%), the product is homogeneous according to those in system A, jl 0.34, -35 ° (with 0.5, 50% acetic acid in distilled water).
    Analysis for amino acids: 0.96 Eli 0.94 Glu, 0.96 Apr, 1.00 Gly.
    Example III: NA 1 Bzl-Mley-GlnGli-Arg-pNA (mol. Weight. 733.2).
    Ilia: Kbo-Gln-Gli-Arg (N02) -nHA (mol. Weight 658.5).
    2.65 g (5 mmol) of the Kbo-Gly-Arg compound (NOj); pNA decarbobenzoxylate with hydrogen bromide in acetic acid and copulated with 2.2 g, (5.5 mmol) of Kbo-Gln-OPNF according to the method described in Example 1a . The crude product is purified by double recrystallization from methanol.
    Yield 2.07 g, (63%) Ilia. Homogeneity according to TLC in system A (RI 0.62), -23 (with 0.5 methanol / dimethylformamide 9/1).
    IIIb: Tert-Boc-Eli-Gln-Gly-Arg (N02) -nHA (mol. Weight 737.6).
    0.66 g (1 mmol) of the Ilia compound is decarbobenzoxylated with hydrogen bromide in AcOH according to the method described in Example 1a. The resulting compound is dissolved in 10 ml of distilled dimethylformamide. The solution is cooled to and the triethylamine is added to neutrality. The triethylamine hydrobromide precipitated was precipitated, the filtrate was cooled again and 0.40 g (1.1-1 out of 5ol) of Boc-Eli-PNP was added to it and the solution was slowly heated to room temperature. After 3 hours, the solution is again cooled to -10 ° C and 0.1 Gll is buffered. (0.7 mmol) triethanol amine, Buffering is repeated after 2-3 hours. The reaction solution is left until morning and an excess of tert-Boc-EI-OPNF is reacted with 0.1 ml (1 mmol) of n-butylamine. After 30 minutes, the solution is evaporated in vacuo at 40 ° G. The remaining yellow oil is mixed thoroughly with 100 ml of distilled water. The water is decanted and the washing is carried out twice more. The residual oil is dissolved in methanol and purified in a Sephadexrm ZH-20 column in methanol using methanol as an eluent. Yield 0.56 g (76%). TLC homogeneity in system A (Rf 0.66.).
    II1c. Bel-Gln-Gly- Arg (N02) 4iHA mol. weight 741.6).
    0.56 (0.76 mmol) of the product Illb is dissolved in 5 ml of trifluoroacetic acid. The solution is stirred for 15 minutes at room temperature, and then slowly poured into 100 ml of vigorously stirred dry ether. The ether is separated by decantation and the precipitate is treated twice with 50 ml of ether. After drying in vacuum over and KOH tablets at 30 ° C, the trifluoroacetic salt of the tetrapeptide derivative is obtained almost quantitatively. The product is homogeneous according to the thin-layer chromatogram in system A.
     The compound obtained is dissolved in 8 ml of dimethylformamide, cooled to -10 ° C and neutralized with triethanolamine. Add 0.23 g (1 mmol) of benzoic anhydride and, after 30 minutes, add another 1.00 µL of triethanolamine. The reaction solution is left overnight and is evaporated in vacuo at. The remaining crude oil is mixed thoroughly with distilled water. Water is decanted, the remaining oil is dissolved in methanol and purified in a column containing Sephadex ZH-20 in Metaiol. Yield 0.55 g (95%). The homogeneity of those in the system A (Rf 0.64).
    Hid Bzl-Eli-Gly-Gln-Arg-pNA-HC1 (mol. Weight 733.3).
    0.55 g (0.75 mmol) III is reacted with hydrofluoric acid, purified (ion exchange) according to the method described in Example 1e. Yield 0.34 g (62%), Homogeneity by TLC in system A (Rf 0.41), -40 (with 0.5, 50% acetic acid in distilled water).
    The remaining intermediate and final products used as examples were synthesized according to the methods described in examples I-III.
    权利要求:
    Claims (2)
    [1]
    The preparation of these compounds and their properties are shown in the table. 139 claims. 1. A method for producing peptides of the general formula K -A-A2-Gly - Apr-NHR2, where R is hydrogen / benzoyl; RJ - N-nitroanilide; A | - asparaginyl, glycyl, isoleucyl, leucyl, valyl, prolyl, tyrosyl, phenylalanil; AJ is glutamic acid, glutamine, aspartic acid, or their salts, characterized in that the compound of the general formula, in which Rj has the indicated values, is subjected to mutual action with the corresponding amino acid and further the desired peptide structure is gradually increased by combining the remaining amino acids, the group R is used as a protecting group for the C-terminus of the carboxyl group of the first amino acid.
    [2]
    2. The method according to claim 1, wherein it is so that in order to build up the desired peptide structure, combinations of amino acids are used by the method of activated esters. ; Sources of information taken into account in the examination 1. Schroeder E., Lubke K. Peptides, Part 1, M., Itop, 1967, p. 116.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU957762A3|1982-09-07|Process for producing peptides or their salts
    US4229438A|1980-10-21|Nonapeptides
    US4350627A|1982-09-21|Biologically active peptides
    US4214049A|1980-07-22|Assay of serine proteases using novel chromogenic enzyme substrates
    Han et al.1975|Studies on the Primary Structure of Bovine High-MolecularWeight Kininogen: Amino Acid Sequence of a Fragment | Released by Plasma Kallikrein
    US4137225A|1979-01-30|Novel chromogenic enzyme substrates
    WO1979000602A1|1979-08-23|Easily split substrates for the quantification of proteases
    Urry et al.1974|Studies on the conformations and interactions of elastin. Proton magnetic resonance of the repeating tetramer
    US4247454A|1981-01-27|Novel chromogenic thrombin substrates
    FI56525C|1980-02-11|NYA KROMOGENA TROMBINSUBSTRAT
    Yamashiro et al.1972|PREPARATION OF Nα‐BOC‐Nε‐P‐BRZ‐LYSINE AND Nα‐BOC‐0‐M‐BRBZL‐TYROSINE AND THEIR USE FOR THE SOLID PHASE SYNTHESIS OF AN OCTAPEPTIDE OCCURRING IN THE HGH MOLECULE
    BLANOT et al.1979|SYNTHESIS OF ANALOGS OF THE SERUM THYMIC NONAPEPTIDE, FACTEUR THYMIQUE SERIQUE | Part I
    Noda et al.1990|A facile method for preparation of t‐butyloxycarbonylamino acid p‐nitroanilides
    GB1584669A|1981-02-18|Process for synthesising peptides containing a sulphated tyrosine residue
    JP2887765B2|1999-04-26|Symmetric bipeptides containing polyalkylene glycol residues, methods for their preparation and use in protease assays
    US4162941A|1979-07-31|Method for determining a proteolytic enzyme
    EP0132919B1|1986-10-29|Peptides
    US6448031B1|2002-09-10|Process for producing LH-RH derivatives
    OGAWA et al.1978|Studies on Peptides. LXXVIII. Synthesis of the Nonacosapeptide corresponding to the Entire Amino Acid Sequence of Avian Glucagon |
    US3826794A|1974-07-30|Protected decapeptide derivatives of gonadotropin releasing hormone
    US4701499A|1987-10-20|Synthesis of N-substituted peptide amides
    FujINo et al.1978|Synthesis of Porcine Motilin and Its D-Phe1-Analog by the Use of Methanesulfonic Acid
    US3784535A|1974-01-08|Nonapeptide intermediate to gonadotropin releasing hormone
    KAWASAKI et al.1994|Amino acids and peptides. XXI. Laminin-related peptide analogs including poly | hybrids and their inhibitory effect on experimental metastasis
    US3655636A|1972-04-11|Process for the synthesis of peptides using 4-pyridylmethyl and related groups for the protection of c-terminal carboxyl groups
    同族专利:
    公开号 | 公开日
    DE2552570C3|1983-11-17|
    CH619983A5|1980-10-31|
    ATA900775A|1978-03-15|
    JPS5431397B2|1979-10-06|
    DK145461C|1983-04-18|
    DE2552570A1|1976-06-10|
    ES442997A1|1977-04-16|
    DE2552570B2|1980-01-10|
    JPS5183595A|1976-07-22|
    BE836085A|1976-03-16|
    FR2293439B1|1979-07-13|
    DK145461B|1982-11-22|
    IL48506D0|1976-01-30|
    GB1488987A|1977-10-19|
    ZA757441B|1976-11-24|
    PL99020B1|1978-06-30|
    NO753945L|1976-06-09|
    HU174263B|1979-12-28|
    DD123316A5|1976-12-12|
    DK549475A|1976-06-06|
    NL7513505A|1976-06-09|
    AT351565B|1979-08-10|
    IL48506A|1979-05-31|
    NL188648B|1992-03-16|
    US4252715A|1981-02-24|
    FR2293439A1|1976-07-02|
    FI753246A|1976-06-06|
    NO142074C|1980-06-25|
    NL188648C|1992-08-17|
    SE7415229L|1976-06-06|
    CA1048998A|1979-02-20|
    AU8687275A|1977-06-02|
    NO142074B|1980-03-17|
    CS187492B2|1979-01-31|
    IT1052318B|1981-06-20|
    SE407058B|1979-03-12|
    US4028318A|1977-06-07|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1042487A|1964-06-25|1966-09-14|Ici Ltd|Polypeptide derivatives|
    US3778426A|1970-12-16|1973-12-11|Research Corp|Therapeutically useful polypeptides|
    SE380257B|1972-05-02|1975-11-03|Bofors Ab|NEW DIAGNOSTIC OPERATING SUBSTRATES WITH HIGH SPECIFICITY FOR THROMBIN AND OTHER PROTEOLYTIC ENZYMES OF THE PEPTIDYL-PEPTIDE HYDROLASES|
    SE407058B|1974-12-05|1979-03-12|Kabi Ab|NEW CHROMOGENA ENZYME SUBSTRATE FOR SERINE PROTEASES|SE407058B|1974-12-05|1979-03-12|Kabi Ab|NEW CHROMOGENA ENZYME SUBSTRATE FOR SERINE PROTEASES|
    SE407571B|1975-07-11|1979-04-02|Kabi Ab|NEW CHROMOGENA ENZYME SUBSTRATE FOR SERINE PROTEASES|
    SE431201B|1976-01-24|1984-01-23|Ajinomoto Kk|FOR USE IN SATURDING OF COLLAGENA ACTIVITY PROVIDED PEPTIDE DERIVATIVE EQUIPMENT|
    US4176009A|1976-01-24|1979-11-27|Ajinomoto Co., Inc.|Method of measuring collagenase activity|
    CH634662A5|1976-05-28|1983-02-15|Pentapharm Ag|USE OF TRIPEPTIDE DERIVATIVES FOR THE QUANTITATIVE DETERMINATION OF PLASMINOGEN ACTIVATORS.|
    CA1087075A|1977-08-05|1980-10-07|Robert J. Gargiulo|Composition and method for determining transferase and protease activity|
    SE437153B|1976-12-01|1985-02-11|Kabi Ab|SPECIFIC CHROMOGENA ENZYM SUBSTATE FOR SERINE PROTEASES|
    US4191809A|1977-02-26|1980-03-04|Ajinomoto Co., Inc.|Method of measuring enzymatic activity using novel peptide derivatives|
    JPS5727720B2|1977-06-14|1982-06-11|
    US4438029A|1978-01-19|1984-03-20|Research Corporation|Synthetic peptides|
    SE7801373L|1978-02-07|1979-08-08|Kabi Ab|EASY SPLABLE SUBSTRATE FOR QUANTIFIATION OF PROTEASES|
    US4275153A|1978-08-03|1981-06-23|American Hospital Supply Corporation|Analytical fluorogenic substrates for proteolytic enzymes|
    US4336186A|1978-08-03|1982-06-22|Gargiulo Robert J|Analytical fluorogenic substrates for proteolytic enzymes|
    JPS59499B2|1978-11-02|1984-01-07|Ajinomoto Kk|
    FR2455083B1|1979-04-24|1983-12-16|Jozefonvicz Marcel|
    DE2921216C2|1979-05-25|1993-02-04|Hansjoerg Prof. Dr. 6300 Giessen De Teschemacher|
    DE2936543A1|1979-09-10|1981-04-09|Behringwerke Ag, 3550 Marburg|CHROMOGENIC COMPOUNDS|
    US4244865A|1979-12-03|1981-01-13|Abbott Laboratories|α hydroxy tripeptide substrates|
    CA1161432A|1980-02-12|1984-01-31|Lars G. Svendsen|Tripeptide derivatives and their application inassaying enzymes|
    US4301245A|1980-05-29|1981-11-17|Dynasciences Corporation|Chromogenic method of detecting endotoxins in blood|
    DE3164437D1|1980-08-25|1984-08-02|Kabivitrum Ab|Peptide substrates for determination of protease activity|
    JPS6342635B2|1980-09-16|1988-08-24|Torii Yakuhin Kk|
    JPS6342636B2|1980-09-16|1988-08-24|Torii Yakuhin Kk|
    US4406832A|1981-09-03|1983-09-27|Mallinckrodt, Inc.|Peptide-type substrates useful in the quantitative determination of endotoxin|
    US4510241A|1981-09-03|1985-04-09|Mallinckrodt, Inc.|Peptide-type substrates useful in the quantitative determination of endotoxin|
    AT17262T|1981-11-02|1986-01-15|Pentapharm Ag|METHOD FOR THE QUANTITATIVE DETERMINATION OF BLOOD COagulation FACTOR XII IN HUMAN PLASMA.|
    US4448715A|1981-11-02|1984-05-15|University Of Miami|Tagged pyroglu-L-Phe-L-Arg derivatives, substrates and assays for kallikrein|
    CA1247086A|1982-02-17|1988-12-20|Francis R. Pfeiffer|Renally active tetrapeptides|
    DE3211254A1|1982-03-26|1983-09-29|Boehringer Mannheim Gmbh, 6800 Mannheim|METHOD FOR DETECTING THE PRESENCE OF AN ALLERGY AND FOR SPECIFIC DETECTING THE ALLERGY RESPONSIBLE FOR THE ALLERGY|
    DE3244030A1|1982-11-27|1984-05-30|Behringwerke Ag, 3550 Marburg|CHROMOGENIC COMPOUNDS, METHOD FOR THEIR PRODUCTION AND THEIR USE|
    DE3312191C2|1983-04-02|1989-05-11|Karl Mengele & Soehne Maschinenfabrik Und Eisengiesserei Gmbh & Co, 8870 Guenzburg, De|
    FR2546164B1|1983-05-16|1987-07-17|Centre Nat Rech Scient|NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ELASTASE INHIBITORS|
    DE3446714A1|1984-12-21|1986-06-26|Boehringer Mannheim Gmbh|METHOD FOR DETECTING THE PRESENCE OF AN ALLERGY AND FOR SPECIFIC DETECTING THE ALLERGY RESPONSIBLE FOR THE ALLERGY|
    US6297024B1|1998-10-15|2001-10-02|Cell Activation, Inc.|Methods for assessing complement activation|
    US6235494B1|1999-02-08|2001-05-22|The Scripps Research Institute|Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates|
    GB2492104A|2011-06-22|2012-12-26|Job Harenberg|Assay for direct thrombin inhibitors|
    CN108089006B|2016-11-23|2020-09-25|舒泰神（北京）生物制药股份有限公司|Method for calibrating activity of blood coagulation factor X activator|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    SE7415229A|SE407058B|1974-12-05|1974-12-05|NEW CHROMOGENA ENZYME SUBSTRATE FOR SERINE PROTEASES|
    [返回顶部]